Key points from article :
Longevity skincare company OneSkin has secured an unexpected $20 million in Series A growth funding from New York’s Prelude Growth Partners, just months after closing a similar-sized round in November. Founded in 2016 by four Brazilian scientists with expertise in stem-cell biology, bioinformatics, and tissue engineering, the San Francisco-based company focuses on extending “skinspan” – the period during which skin remains healthy and functional. This approach reflects a growing shift in the beauty industry toward longevity science, with big players like L’Oréal also targeting the biological root causes of skin ageing.
OneSkin’s research centres on senescent cells – aged cells that no longer divide but release inflammatory molecules, contributing to tissue breakdown and visible signs of ageing. Its flagship product is OS-01, a proprietary peptide designed to reduce the burden of these cells, aiming to improve skin health at the cellular level rather than just enhancing surface appearance. The company currently sells a range of topicals and supplements, including OS-01 FACE, BODY, and EYE, along with newer products for lips and hair.
Prelude’s investment replaces an early seed investor and is expected to help OneSkin scale its business, broaden its customer base, and accelerate product development. Co-founder Dr Carolina Reis Oliveira described the partnership as a “natural fit,” praising Prelude’s belief in the company’s mission. Prelude, which has a track record of backing female-founded health, beauty, and wellness brands, called OneSkin’s science and brand “truly unique” in the category.
The deal highlights a wider trend of growth capital flowing to consumer brands translating lab research into direct-to-consumer health and beauty products. OneSkin says the fresh funds will support its goal of aligning aesthetic benefits with measurable improvements in skin health, bridging the gap between cosmetics and cellular longevity science.
